ANZCTR search results

Our previous research indicates vapocoolant is effective in significantly decreasing the pain of intravenous cannulation. This new study will compare vapocoolant with subcutaneous lignocaine, another common means of reducing the pain of cannulation.

The goal of this study is to evaluate the safety of increasing doses of an experimental drug called INO-4885. In the earlier, completed parts (Parts 1 and 2) of this study, a single dose on INO-4885 at 1-600 micrograms per kilogram body weight was given to healthy male volunteers via a catheter placed in an arm vein. In Part 3 of this study, one dose of 1200 micrograms per kilogram body weight will be given to healthy male volunteers. Safety assessments will include physical examinations, routine blood and urine tests, electrocardiograms, blood and urine levels of INO-4885, and other indicators of safety will be recorded and analyzed.

Aim: to determine whether the web-based Bipolar Education Program (BEP) improves understanding and control of bipolar disorder, as well as mood, functioning and psycho-social adjustment in adults with newly diagnosed with bipolar disorder, in comparison with a minimal online education control condition. Two versions of the bipolar education program will be evaluated:(a)on its own and (b)with email support from an informed supporter who will also provide structured assistance to implement a ‘stay-well’ self-management plan. Informed supporters are people with bipolar disorder who are effectively self-managing their condition and who will be trained to provide online support for the education program under supervision of our clinical team. Hypotheses: At post-intervention and follow-up (3 and 6 months post-intervention): 1. Participants who receive the Bipolar Education Program (BEP) will have greater understanding of bipolar disorder, report greater control and self-management of their condition, and experience a better illness trajectory (fewer depressive and manic/hypomanic episodes, symptoms and impairment, fewer hospitalizations) and better psycho-social functioning than the attention control group. 2. Participants who receive the full BEP package (BEP + email support from an informed supporter with assistance to develop and implement a ‘stay well’ plan) will have greater understanding of bipolar disorder, report greater control and self-management of their condition, and experience a better illness trajectory (fewer depressive and manic/hypomanic episodes, symptoms and impairment, fewer hospitalizations) and better psycho-social functioning than people receiving the BEP alone or the attention control condition. 3. People receiving the full BEP package will report greater satisfaction with the intervention than those in the other BEP conditions and in the attention control condition. 4. The health service costs associated with hospitalizations and visits to health practitioners will be significantly different between the groups.

OSA is a condition in which a person stops breathing for several seconds at a time due to relaxation of the throat muscles. This can occur many times over during sleep. It is known to cause sleepiness and poor concentration during the day. Research indicates that OSA may be a modifiable risk factor for cardiovascular disease due to its association with hypertension, stroke, heart attack and sudden death. The standard therapy for symptomatic OSA is CPAP. CPAP has been shown to effectively reduce snoring, obstructive episodes and daytime sleepiness and to modestly reduce blood pressure and other risk factors for cardiovascular disease. The overall aim of SAVE is to determine if CPAP can reduce the risk of heart attack, stroke or heart failure for people with OSA.

The primary objective of this study is to evaluate and determine the types of complications and benefits from the transthoracic pneumonostomy procedure in patients with severe emphysema (homogeneous). The results from this study will provide the profile for safety and feasibility of use of the pneumonostomy device system and support subsequnt trials with larger number of patients.

Nutritional support is accepted as a standard of care for critically ill patients although there is little agreement as to how it is best provided. Use of evidence-based guidelines has been shown to improve the effectiveness of care. The purpose of this project is to develop, promote and evaluate evidence-based clinical practice guidelines for nutritional support in the ICU in twenty-six hospitals throughout Australia and New Zealand. One half of the hospitals will be randomised to receive educational sessions based on the content of the guidelines using previously proven and accepted educational strategies. A cluster randomised trial will then evaluate the impact of these educational sessions on acceptance of the guideline and on patient outcomes.

The primary aim of this project is to determine if the study drug, Pyridorin™, at doses of 150mg orally twice daily or 300mg orally twice daily (compared to placebo), has an effect on the blood values (specifically serum creatinine) of subjects' who have kidney disease from type 2 diabetes.

This study looks at the effectiveness of the appetite stimulating drugs megestrol and dexamethasone in treating anorexia in the palliative care of people with widespread and advanced cancer. Who is it for? You can join this study if you have widespread and advanced cancer and suffer from loss of appetite. Trial details Participants will be divided into two groups. One group will receive the drug megestrol acetate and the other will receive dexamethasone. Both groups will be monitored for appetite levels and quality of life, along with any weight gain, improved function and side effects. Despite encouraging results from a US study, megestrol is not currently prescribed extensively as an appetite stimulant to Australians with advanced cancer, primarily due to its cost.

The trial is a randomised phase II open-label multicentre trial investigating oral fludarabine, cyclophosphamide and intravenous rituximab in previously untreated elderly (= 65 years old) patients with chronic lymphocytic leukaemia. The primary objective is to investigate the tolerability of each of three of these combination chemotherapies and the associated primary endpoint is the proportion of paitens able to complete 6 cycles of therapy.

This study will be used to investigate whether the addition of oxaliplatin to preoperative fluoropyrimidine-based chemoradiation and postoperative fluoropyrimidine-based chemotherapy improves disease-free survival in locally advanced rectal cancer.